Cite
HARVARD Citation
Gainor, J. et al. (2017). J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer. Lancet. 390 (10089), pp. 3-4. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Gainor, J. et al. (2017). J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer. Lancet. 390 (10089), pp. 3-4. [Online].